San Francisco, CA--January 13, 2016 Verseon (AIM: VSN). Dr. David Kita, Verseon’s co-founder and Vice President of Research and Development, presented preclinical data on the company’s new class of anti-coagulants at the 8th annual Biotech Showcase yesterday - January 12th. Kita’s presentation included recently obtained data on a number of drug candidates in this new class that demonstrates continuing and steady progress in Verseon’s anticoagulation program.
Verseon is a technology-based pharmaceutical company that uses their own proprietary and patented computational drug discovery platform to research and develop novel drugs and drug therapies for unmet medical needs.
The Company’s new class of oral, highly selective, direct thrombin inhibitors have been proven in preclinical efficacy studies and also show pharmacokinetic profiles suitable for oral dosing. Verseon’s compounds demonstrate reduced risk of major bleeding relative to current novel oral anticoagulants (NOACs).
Kita said, “the data we have obtained in our anticoagulant program represents comprehensive preclinical, scientific evidence that Verseon’s compounds have lower bleeding risk than conventional therapies with equivalent or better therapeutic potential. This data will form an important part of our upcoming IND (Investigational New Drug) filings for this program.”
Forward-Looking Statements:
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors.
Notes to editors:
Verseon is a pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics for today’s challenging diseases. The Company is applying its platform to a growing drug pipeline and has three active drug programs in the areas of anticoagulation, diabetic macular edema, and solid tumor cancers.
FOR MEDIA INFORMATION:
Simon Vane Percy
Vane Percy & Roberts
(T) 01737 821890
(M) 07710 005 910
